글로벌 키메라 항원 수용체(CAR)-T 세포 치료 시장 규모, 점유율 및 추세 분석 보고서 – 산업 개요 및 2031년까지의 예측

키메라 항원 수용체(CAR)-T 세포 치료 시장 분석

키메라 항원 수용체(CAR)-T 세포 치료 시장은 혁신적인 연구와 임상 응용에 의해 주도되어 놀라운 발전을 이루었습니다. 환자의 T 세포를 변형하여 암 세포를 표적으로 삼아 공격하는 CAR-T 세포 치료는 급성 림프모구 백혈병 및 비호지킨 림프종과 같은 다양한 혈액 악성 종양을 치료하는 데 상당한 효능을 보였습니다 . 최근 개발에는 새로운 CAR-T 제품 도입, 향상된 제조 공정 및 새로운 표적 항원의 탐색이 포함되어 환자 결과가 개선되었습니다. 예를 들어 Max Healthcare와 같은 회사는 기관과 협력하여 CAR-T 치료법을 출시하여 이러한 혁신적인 치료법에 대한 접근성을 확대했습니다. 또한 특히 북미와 아시아 태평양 지역에서 임상 시험에 대한 투자가 증가함에 따라 경쟁 환경이 조성되어 추가 혁신이 촉진되고 있습니다. 이 치료법이 계속해서 인기를 얻으면서 규제 기관은 승인 절차를 신속히 진행하여 생명을 구하는 치료법에 더 빨리 접근할 수 있도록 적응하고 있습니다. 이러한 역동적인 시장 환경은 견고한 성장을 이룰 것으로 보이며, CAR-T 치료의 적응증 확대와 치료 방법 개선에 초점이 맞춰지면서 의료 서비스 제공자, 환자, 제약 회사 모두에게 유망한 기회를 제공합니다.

키메라 항원 수용체(CAR)-T 세포 치료 시장 규모

글로벌 키메라 항원 수용체(CAR)-T 세포 치료 시장 규모는 2023년에 24억 4천만 달러로 평가되었으며, 2031년까지 59억 7천만 달러에 도달할 것으로 예상되며, 2024년에서 2031년까지의 예측 기간 동안 CAGR은 11.80%입니다. Data Bridge Market Research에서 큐레이팅한 시장 보고서에는 시장 가치, 성장률, 세분화, 지리적 범위, 주요 업체와 같은 시장 시나리오에 대한 통찰력 외에도 심층 전문가 분석, 환자 역학, 파이프라인 분석, 가격 분석 및 규제 프레임워크도 포함됩니다.

키메라 항원 수용체(CAR)-T 세포 치료 시장 동향

“ 이종 CAR-T 세포 치료법으로의 전환 증가”

키메라 항원 수용체(CAR)-T 세포 치료 시장은 혁신적인 연구와 임상 응용에 의해 주도되어 놀라운 발전을 이루었습니다. 키메라 항원 수용체(CAR)-T 세포 치료 시장에서 두드러진 추세 중 하나는 건강한 기증자의 유전자 변형 T 세포를 환자 자신의 세포가 아닌 활용하는 이종 CAR-T 세포 치료로의 전환입니다. 이러한 접근 방식은 접근성을 높이고 자가 치료와 관련된 제조 시간과 비용을 줄이는 것을 목표로 합니다. 예를 들어, Allogene Therapeutics와 같은 회사는 환자가 쉽게 사용할 수 있는 기성품 CAR-T 치료를 개발하여 치료 시작을 기다리는 시간을 최소화합니다. 이종 CAR-T 치료의 편의성은 특히 급성 림프모구 백혈병과 같이 시간이 중요한 긴급한 경우 환자의 결과를 크게 개선할 수 있습니다. 또한, 지속적인 임상 시험과 규제 지원이 이 부문의 혁신을 주도하고 있으며, 이를 통해 이종이식 CAR-T 세포 치료법이 암 치료의 미래 발전을 위한 초점이 되고 다양한 환자 집단으로 시장의 잠재적 도달 범위를 확대할 것입니다.

보고서 범위 및 키메라 항원 수용체(CAR)-T 세포 치료 시장 세분화

Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Definition

Chimeric antigen receptor (CAR)-T cell therapy is an innovative form of immunotherapy that involves genetically modifying a patient's T cells to express chimeric antigen receptors. These receptors are designed to recognize specific antigens present on the surface of cancer cells. Once the T cells are modified, they are expanded in the laboratory and then infused back into the patient, where they seek out and attack the cancer cells, thereby enhancing the body’s immune response against tumors. This therapy has shown significant effectiveness in treating certain hematologic cancers, such as acute lymphoblastic leukemia and non-Hodgkin lymphoma, and is being investigated for use against various solid tumors and other malignancies.

Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Dynamics

Drivers

• Rising Incidence of Cancer

The global rise in cancer cases has significantly increased the demand for Chimeric Antigen Receptor (CAR)-T cell therapy among healthcare providers treating cancer patients. According to the Centers for Disease Control and Prevention (CDC), in 2019, the United States reported 1,752,735 new cancer diagnoses and 599,589 cancer-related deaths. This translates to approximately 439 new cancer cases and 146 cancer deaths for every 100,000 individuals in the population. The alarming prevalence of cancer is driving healthcare providers to increasingly adopt CAR-T cell therapy due to its numerous benefits, including targeted treatment and personalized approaches, which are expected to further propel market growth. This trend underscores the therapy's potential as a vital component in the fight against cancer, ultimately enhancing patient outcomes and survival rates.

• Rising Product Approvals

The increasing number of product approvals significantly contributes to the growth of the chimeric antigen receptor (CAR)-T cell therapy market. For instance,  the approval of CARVYKTI by the Janssen Pharmaceutical Companies of Johnson & Johnson in 2022, which received U.S. FDA clearance for treating adults with relapsed or refractory multiple myeloma (RRMM) who have undergone four or more prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody. Such advancements in approvals not only enhance treatment options for patients but also reinforce the market's momentum by encouraging further investment and research in CAR-T cell therapies. Consequently, the growing trend of product approvals is expected to be a significant driver of market growth in this sector.

Opportunities

• Rising Investments from Key Organizations

The growing investments in chimeric antigen receptor (CAR-T) cell therapy are significantly driving market expansion. For instance, in 2021, Blackstone announced that funds managed by Blackstone Life Sciences committed USD 250 million to establish a new company focused on both autologous and allogeneic universal CAR-T cell therapies, collaborating with Intellia Therapeutics, Inc. and Cellex Cell Professionals GmbH. This substantial financial backing is expected to accelerate research and development efforts, ultimately leading to innovative therapies and improved treatment options for patients. Such investments enhance the therapeutic landscape and represent a significant market opportunity, as they pave the way for advancements in CAR-T cell therapies that can address unmet medical needs and improve patient outcomes.

• Increasing Cases of Multiple Myeloma

The rising incidence of multiple myeloma is projected to drive significant growth in the market for chimeric antigen receptor (CAR)-T cell therapies. According to GLOBOCAN 2020, approximately 176,000 new cases of multiple myeloma and immunoproliferative diseases were expected in 2020, with projections suggesting this figure could soar to 290,000 by 2040. Furthermore, the data indicates that individuals have a 1 in 117 chance of being diagnosed with multiple myeloma by the age of 85. This increasing prevalence highlights a critical market opportunity for CAR-T cell therapies, as healthcare providers seek innovative treatment options to address the growing patient population. The anticipated rise in cases underscores the urgent need for effective therapies, driving demand for CAR-T solutions that can offer improved outcomes for patients suffering from this challenging condition.

Restraints/Challenges

• Adverse Effects of Chimeric Antigen Receptor (CAR)-T Cell Therapy

Chimeric antigen receptor (CAR) T-cell therapies are associated with significant side effects that can hinder market growth. One of the most critical challenges is the occurrence of cytokine release syndrome (CRS), which has been identified as one of the most common and severe adverse reactions to these treatments. CRS results from the rapid activation and proliferation of CAR T-cells, leading to the release of large quantities of cytokines, which are chemical messengers that modulate immune responses. This uncontrolled release can cause symptoms ranging from mild flu-like effects to severe, life-threatening complications such as high fever, low blood pressure, and multi-organ failure. In addition, the mass destruction of antibody-producing B cells can leave patients vulnerable to infections, further complicating their treatment journey. These serious side effects pose significant challenges for healthcare providers and patients alike, potentially limiting the widespread adoption of CAR T-cell therapies and restraining overall market growth.

• Significant Expenses Related to Chimeric Antigen Receptor (CAR)-T Cell Therapy

The substantial costs associated with CAR T-cell therapy pose a significant challenge to market growth, as they can restrict access for many patients who need this advanced treatment. The price of a single CAR T-cell therapy treatment can be exceptionally high, making it unaffordable for a large segment of the population, particularly those without adequate insurance coverage. This financial barrier limits patient access and places an enormous strain on healthcare systems, which must allocate resources to cover these expensive treatments. As a result, disparities in treatment availability may emerge, with wealthier patients gaining access while others are left without options, ultimately hindering the broader adoption and equitable distribution of CAR T-cell therapies. This situation highlights the challenge of integrating these cutting-edge therapies into standard care pathways.

This market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Scope

The market is segmented on the basis of types, target antigen, and therapeutic application. The growth amongst these segments will help you analyse meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Types

• Abecma
• Breyanzi
• Kymriah
• Tecartus
• Yescarta
• Others

Target Antigen

• CD 19
• CD 20
• GD2
• CD22
• CD30
• CD33
• HER1
• HER2
• Meso
• Egfrvlll
• Others

Therapeutic Application

• Acute Lymphocytic Leukemia
• Chronic Lymphocytic Leukemia
• Non-Hodgkin Leukemia
• Multiple Myeloma
• Pancreatic Cancer
• Neuroblastoma
• Breast Cancer
• Acute Myeloid Leukemia
• Hepatocellular Carcinoma
• Colorectal Cancer
• Others

Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Regional Analysis

The market is analysed and market size insights and trends are provided by country, types, target antigen, and therapeutic application as referenced above.

The countries covered in the market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America leads the chimeric antigen receptor (CAR)-T cell therapy market, driven by a strong foundation in research and commercialization. The region's advanced healthcare infrastructure and investment in innovative therapies contribute significantly to this dominance. Furthermore, the surge in clinical trials focused on T-cell therapies is expected to bolster market growth in North America throughout the forecast period.

Asia-Pacific region is anticipated to experience significant growth in the chimeric antigen receptor (CAR)-T cell therapy market, primarily due to the highest number of registered clinical trials related to these therapies. Governments in the region are making substantial investments and implementing reforms to enhance healthcare infrastructure, which will further stimulate market expansion. As these initiatives progress, they are expected to create a more favorable environment for the development and adoption of CAR-T cell therapies in the coming years.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.  

Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Share

The market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to market.

Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Leaders Operating in the Market Are:

• Autolus Therapeutics (U.K.)
• CARsgen Therapeutics Holdings Limited (U.K.)
• Bristol-Myers Squibb Company (U.S.)
• Sorrento Therapeutics, Inc. (U.S.)
• bluebird bio, Inc. (U.S.)
• Eureka Therapeutics Inc. (U.S.)
• Avacta Group plc (U.K.)
• Cibus Inc. (France)
• Celyad Oncology SA (Belgium)
• Fortress Biotech, Inc. (U.S.)
• Gilead Sciences, Inc. (U.S.)
• Novartis AG (Switzerland)
• Alaunos Therapeutics, Inc. (U.S.)
• Poseida Therapeutics, Inc. (U.S.)

Latest Developments in Chimeric Antigen Receptor (CAR)-T Cell Therapy Market

• In December 2023, Max Healthcare successfully introduced CAR-T cell therapy in the Delhi-NCR area, marking a significant advancement in cancer treatment options. This innovative therapy, developed in partnership with ImmunoACT, is specifically designed to combat lymphomas and leukemias, offering new hope for patients battling these challenging conditions
• In December 2022, CARsgen Therapeutics Co., Ltd. partnered with the Shanghai Cancer Institute to develop new technology that significantly enhances the antitumor effectiveness of T cells. Their research team discovered that CAR T cells engineered to overexpress Runx3 exhibited sustained antitumor activity and improved tumor control compared to traditional chimeric antigen receptor T-cell therapies
• In November 2022, Caribou Biosciences, Inc. announced that its allogeneic anti-CD19 CAR-T cell therapy, CB-010, received Regenerative Medicine Advanced Therapy (RMAT) designation from the U.S. Food and Drug Administration (FDA) for relapsed or refractory large B cell lymphoma (LBCL), as well as fast track designation for relapsed or refractory B cell non-Hodgkin lymphoma
• 2022년 6월, 오타와 대학교는 캐나다 주도의 암 면역 요법-01(CLIC-01) 임상 시험에서 유망한 결과를 선보였는데, 이는 캐나다에서 개발한 최초의 암 CAR-T 세포 요법 중 하나에 초점을 맞추었습니다. 이 요법은 더 저렴하고 공평한 치료 옵션으로 이어질 수 있는 독특한 제조 공정을 특징으로 합니다.
• 2021년 11월, 캘리포니아 재생 의학 연구소의 이사회는 캘리포니아 대학교 샌디에이고 의과대학의 과학자들이 개발 중인 혁신적인 키메라 항원 수용체 T 세포 치료법의 발전을 지원하기 위해 410만 달러의 보조금을 승인했으며, 이는 이 유망한 암 치료법을 실험실에서 임상으로 전환하려는 그들의 노력을 지원합니다.

SKU-44836